Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function.Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years.With the failure of these inhibitors in clinical trials,more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs , a brief description of available threedimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
Keywords: Matrix metalloproteinases, MMP inhibitors, Zinc-binding groups, cancer, computer-aided drug design, angiogenesis, metastasis, proteases
Current Medicinal Chemistry
Title: Progress in the Development of Matrix Metalloproteinase Inhibitors
Volume: 15 Issue: 14
Author(s): GuoGang Tu, WenFang Xu, HuiMing Huang and ShaoHua Li
Affiliation:
Keywords: Matrix metalloproteinases, MMP inhibitors, Zinc-binding groups, cancer, computer-aided drug design, angiogenesis, metastasis, proteases
Abstract: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function.Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years.With the failure of these inhibitors in clinical trials,more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs , a brief description of available threedimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
Export Options
About this article
Cite this article as:
Tu GuoGang, Xu WenFang, Huang HuiMing and Li ShaoHua, Progress in the Development of Matrix Metalloproteinase Inhibitors, Current Medicinal Chemistry 2008; 15 (14) . https://dx.doi.org/10.2174/092986708784567680
DOI https://dx.doi.org/10.2174/092986708784567680 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Assessment and Management of Loose Bodies in the Knee Joint and Related Disease: A Narrative Review
Current Rheumatology Reviews Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Achievements and Challenges of Proteomics in the Study of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry CENPA a Genomic Marker for Centromere Activity and Human Diseases
Current Genomics Patent Selections
Recent Patents on Drug Delivery & Formulation Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Anti-Arthritic Effect of Garcinol Enriched Fraction Against Adjuvant Induced Arthritis
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Trace Elements Supplementation: Recent Advances and Perspectives
Mini-Reviews in Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Structure-Based Design of Benzimidazole Sugar Conjugates: Synthesis, SAR and In Vivo Anti-inflammatory and Analgesic Activities
Medicinal Chemistry The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets